The importance of synthetic chemistry in the pharmaceutical industry

Science ◽  
2019 ◽  
Vol 363 (6424) ◽  
pp. eaat0805 ◽  
Author(s):  
Kevin R. Campos ◽  
Paul J. Coleman ◽  
Juan C. Alvarez ◽  
Spencer D. Dreher ◽  
Robert M. Garbaccio ◽  
...  

Innovations in synthetic chemistry have enabled the discovery of many breakthrough therapies that have improved human health over the past century. In the face of increasing challenges in the pharmaceutical sector, continued innovation in chemistry is required to drive the discovery of the next wave of medicines. Novel synthetic methods not only unlock access to previously unattainable chemical matter, but also inspire new concepts as to how we design and build chemical matter. We identify some of the most important recent advances in synthetic chemistry as well as opportunities at the interface with partner disciplines that are poised to transform the practice of drug discovery and development.

Author(s):  
Zaffar Ahmed Shaikh ◽  
Ali Orangzeb Panhwar ◽  
Kamlesh Kumar ◽  
Irfan Ahmed Solangi ◽  
Abida Parveen Panhwar

Medicine has displayed miraculous developments during the past century or so. Credit goes to the emergence of scientific research methods. Research on the disease, its causes, effects, precaution, and especially cure has revolutionized the world. Man has been liberated from epidemics and other deadly diseases. All this would not have been possible, had there not been research and development in medication simultaneously. The pharmaceutical industry is an integral part of the medical field. A real boost was given to all kinds of research with the invention of the computer. Data saving, processing, and analysis were never easier. This paper aims at highlighting the great role and importance of Pharmacoinformatics in drug discovery. It also elucidates how drug discovery is done. A portion of it also targets how this science has evolved over time. The particular purpose is to trace the transformations that came with the introduction of Information Technology in this field.


2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.


2018 ◽  
Vol 32 (5) ◽  
pp. 302-311 ◽  
Author(s):  
Elizabeth K. McClain ◽  
Yolanda Johnson-Moton ◽  
Bryan Larsen ◽  
Rebecca J. Bartlett Ellis ◽  
Eric Niederhoffer

The approach to building innovative partnerships between academia and the pharmaceutical industry has expanded to investigate collaborations that offer meaningful outcomes beyond discovery and increased productivity. This case study uses a systems thinking approach to guide the process and analyse the outcome of a partnership undertaken by one pharmaceutical company and academia. The collaborative process established three tiers of evolution over a 3-year period. The outcome was an online module–based course, entitled ‘Making Medicines: The Process of Drug Development’, that provides information about the drug discovery and development process. Both the course development and the final product serve as a useful case study of how collaboration between academia and industry might be achieved. The development process itself is proposed as an appropriate approach for building educational partnerships.


2005 ◽  
Vol 11 (4) ◽  
Author(s):  
Mark J Belsey ◽  
Alex K Pavlou

As part of Datamonitor's alliance and licensing strategic analysis, the authors have completed a two year survey of the trends underlying early-stage drug discovery and development collaborations between October 2002 and September 2004, which included 524 early-stage deals. Deal analysis shows that the leading pharma and biotech companies (fully integrated players) are the principal collaboration seekers, and that target and product innovation is driving the new wave of 21st century deals. These deals cover all phases of early-stage drug development, with lead product/target identification/validation accounting for the greatest proportion of collaborations. This represents a shift away from initial-stage collaborations, which are primarily focused on technologies such as genomics, as a result of the lack of tangible results that such technologies have delivered in the past. Following the continuously increasing demand for late-stage high-value products, the aim of the money and time invested in these early-stage collaborations is to reverse the pipeline productivity crisis currently affecting the industry's leaders over the mid to long term.


2012 ◽  
Vol 23 (21) ◽  
pp. 4162-4164 ◽  
Author(s):  
Peter K. Sorger ◽  
Birgit Schoeberl

The profound challenges facing clinicians, who must prescribe drugs in the face of dramatic variability in response, and the pharmaceutical industry, which must develop new drugs despite ever-rising costs, represent opportunities for cell biologists interested in rethinking the conceptual basis of pharmacology and drug discovery. Much better understanding is required of the quantitative behaviors of networks targeted by drugs in cells, tissues, and organisms. Cell biologists interested in these topics should learn more about the basic structure of drug development campaigns and hone their quantitative and programming skills. A world of conceptual challenges and engaging industry–academic collaborations awaits, all with the promise of delivering real benefit to patients and strained healthcare systems.


in education ◽  
2012 ◽  
Vol 18 (1) ◽  
Author(s):  
Patricia Elliott

Supported by a growing body of research, the idea that schools have an essential role to play in local community cohesion and development has gained currency among urban and rural school advocates alike. Yet moving theory into action often grinds to a halt in the face of a recalcitrant bureaucracy. To understand why, it is important to step back and examine the theoretical framework of progress that has driven school consolidation and bureaucratization over the past century. Knowing these underlying power dynamics will help community advocates understand where their power is weakest, and where it is strongest, leading to more effective community action in defence of local schools.Keywords: school consolitation; community action; community school


2018 ◽  
Vol 30 (3) ◽  
pp. 45-56
Author(s):  
Therese Jennissen ◽  
Colleen Lundy

INTRODUCTION: Many challenges that confront social workers today are similar to problems they have faced over the past century – inequality, poverty, unemployment, militarisation and armed conflict, and the challenges of refugee resettlement, to name a few. It is instructive for contemporary social workers to revisit this history and to determine if there are lessons to inform our current struggles.METHOD: This paper explores the issues faced and strategies employed by radical, politically active social workers, most of them women. These social workers had visions of social justice and were not afraid to challenge the status quo, often at very high personal costs. The radical social workers were expressly interested in social change that centred on social justice, women’s rights, anti-racism, international peace, and they worked in close alliance and solidarity with other progressive groups.CONCLUSIONS: This article highlights the work of five radical female social workers. Radical social workers were in the minority but they were extraordinarily active and made important contributions in the face of formidable challenges.


2021 ◽  
Vol 9 ◽  
Author(s):  
Agnieszka Staśkiewicz ◽  
Patrycja Ledwoń ◽  
Paolo Rovero ◽  
Anna Maria Papini ◽  
Rafal Latajka

Peptidomimetics play a fundamental role in drug design due to their preferential properties regarding natural peptides. In particular, compounds possessing nitrogen-containing heterocycles have been intensively studied in recent years. The triazolyl moiety incorporation decreases the molecule susceptibility to enzymatic degradation, reduction, hydrolysis, and oxidation. In fact, peptides containing triazole rings are a typical example of peptidomimetics. They have all the advantages over classic peptides. Both efficient synthetic methods and biological activity make these systems an interesting and promising object of research. Peptide triazole derivatives display a diversity of biological properties and can be obtained via numerous synthetic strategies. In this review, we have highlighted the importance of the triazole-modified peptidomimetics in the field of drug design. We present an overview on new achievements in triazolyl-containing peptidomimetics synthesis and their biological activity as inhibitors of enzymes or against cancer, viruses, bacteria, or fungi. The relevance of above-mentioned compounds was confirmed by their comparison with unmodified peptides.


Sign in / Sign up

Export Citation Format

Share Document